Hematopoietic precursor cell (HPC) (HPC)

Hematopoietic precursor cells (HPCs) are multipotent stem cells located in the bone marrow that give rise to all blood cell lineages, including red blood cells, white blood cells, and platelets (National Cancer Institute, 2024) [1]. These cells are frequently the unintended targets of cytotoxic chemotherapy, such as carboplatin, which causes DNA damage and leads to dose-limiting myelosuppression (PubChem, 2024) [2]. The cytotoxic effect of carboplatin on HPCs is modulated by the administration of paclitaxel, a microtubule-stabilizing agent (PubChem, 2024) [3]. Clinical evidence suggests that the sequence of drug administration is critical; giving paclitaxel before carboplatin can significantly reduce the severity of neutropenia and thrombocytopenia compared to the reverse sequence (Kearns et al., 1995) [4]. This protective effect is hypothesized to occur because paclitaxel induces a transient cell cycle arrest in the HPC population, shielding them from the DNA-damaging effects of carboplatin (Huizing et al., 1997) [5]. Understanding this interaction is essential for optimizing chemotherapy regimens to minimize hematologic toxicity while maintaining anti-tumor efficacy.

Other names

Hematopoietic stem cellHSCHematopoietic progenitor cellBone marrow stem cellMultipotent hematopoietic stem cell

Carboplatin acts by forming reactive platinum complexes that create intra-strand and inter-strand DNA cross-links, inhibiting DNA synthesis and triggering apoptosis in dividing cells (PubChem, 2024) [2]. Paclitaxel stabilizes microtubules by binding to the beta-subunit of tubulin, leading to G2/M phase cell cycle arrest (PubChem, 2024) [3]. The modulation effect occurs when paclitaxel-induced cell cycle arrest in hematopoietic precursors provides a protective "shielding" effect against carboplatin-induced DNA damage, particularly when paclitaxel is administered prior to carboplatin (Kearns et al., 1995) [4].